Back to Search
Start Over
Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients
- Source :
- Endocrine Regulations. 56:265-270
- Publication Year :
- 2022
- Publisher :
- Walter de Gruyter GmbH, 2022.
-
Abstract
- Objective. This study was aimed to evaluate the prevalence of Cushing’s syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients. Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively. Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing’s syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing’s syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl. Conclusions. The prevalence of Cushing’s syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing’s syndrome screening in this patient group.
Details
- ISSN :
- 13360329
- Volume :
- 56
- Database :
- OpenAIRE
- Journal :
- Endocrine Regulations
- Accession number :
- edsair.doi.dedup.....fb4d4a2b7bd9f287b33c3511a20ce9c2